5,6-Dihydro-5,5-dimethyl-2-(4-morpholinyl)-7(4H)-benzothiazolone

CAS : 15091-04-0

Ref. 3D-FD21994

Informations sur le produit

• Nom: 5,6-Dihydro-5,5-dimethyl-2-(4-morpholinyl)-7(4H)-benzothiazolone

Description

5,6-Dihydro-5,5-dimethyl-2-(4-morpholinyl)-7(4H)-benzothiazolone (HMBA) is a compound that has been used as a contrast agent in diagnostic angiography and radiation therapy. HMBA is given intravenously and excreted by the kidneys. It accumulates in the liver, spleen, and other tissues. HMBA can be detected in maternal blood as early as two hours after administration. HMBA is also used to diagnose preeclampsia during pregnancy. The diagnosis of preeclampsia is based on the detection of elevated levels of creatinine phosphokinase (CPK), high levels of uric acid, high blood pressure, proteinuria, and edema. The drug has also been shown to have hepatocyte-like properties in cell culture experiments. This compound has been shown to be useful for the treatment of women with intrauterine growth retardation due

• Marque: Biosynth

Propriétés chimiques

• Masse moléculaire: 266.36 g/mol
• Formule: C₁₃H₁₈N₂O₂S
• Degré de pureté: Min. 95%
• InChI: InChI=1S/C13H18N2O2S/c1-13(2)7-9-11(10(16)8-13)18-12(14-9)15-3-5-17-6-4-15/h3-8H2,1-2H3
• Code InChI: InChIKey=DZXMARZBAUMWLK-UHFFFAOYSA-N
• SMILES: CC1(C)CC(=O)c2sc(N3CCOCC3)nc2C1